AOD-9604 was developed to: Stimulate lipolysis (breakdown of stored fat) Inhibit lipogenesis (formation of new fat) Avoid raising IGF-1 levels Reduce impact on blood glucose Because it is a small fragment rather than the full hormone, it theoretically targets fat metabolism more specifically
These timelines reflect typical clinical observations, not guaranteed outcomes
In experimental contexts, Epithalon is explored for its influence on cellular longevity pathways, melatonin regulation, and genomic stability mechanisms
Even so, RFK Jr
Semax and Selank are Russian-developed peptides with their own thin Western evidence base
ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans